loading

Gilead Sciences Inc 주식(GILD)의 최신 뉴스

pulisher
May 30, 2025

Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold? - The Globe and Mail

May 30, 2025
pulisher
May 30, 2025

Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance By Stocktwits - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Transforming How Cancer Is Treated: Research Results To Be Shared at ASCO25 - CSRwire

May 30, 2025
pulisher
May 30, 2025

Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty - Reuters

May 30, 2025
pulisher
May 30, 2025

Gilead Sciences Plans to Supply Twice-Yearly HIV Prevention Shot to Low-Income Countries Pending FDA Approval - geneonline.com

May 30, 2025
pulisher
May 30, 2025

Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden - ACCESS Newswire

May 30, 2025
pulisher
May 29, 2025

Gilead at Bernstein Conference: Strategic Growth and Innovation - Investing.com

May 29, 2025
pulisher
May 29, 2025

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

May 29, 2025
pulisher
May 29, 2025

Gilead at Bernstein Conference: Strategic Growth and Innovation By Investing.com - Investing.com UK

May 29, 2025
pulisher
May 29, 2025

Transcript : Gilead Sciences, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 02 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance

May 29, 2025
pulisher
May 28, 2025

Gilead Sciences and Kite Pharma To Announce Transformative - CSRwire

May 28, 2025
pulisher
May 27, 2025

Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff - Investing.com Nigeria

May 27, 2025
pulisher
May 26, 2025

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com

May 26, 2025
pulisher
May 26, 2025

Gilead Ready To Go After Hepatitis D Again - insights.citeline.com

May 26, 2025
pulisher
May 26, 2025

Gilead Sciences' Best Days May Be AheadHere's Why (NASDAQ:GILD) - Seeking Alpha

May 26, 2025
pulisher
May 26, 2025

GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

Gilead’s Phase III trial for breast cancer therapy meets primary goal - Clinical Trials Arena

May 26, 2025
pulisher
May 25, 2025

Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump - MSN

May 25, 2025
pulisher
May 24, 2025

Gilead says Trodelvy ASCENT-03 study meets primary endpoint - The Pharma Letter

May 24, 2025
pulisher
May 24, 2025

Gilead announces ASCENT-03 study meets primary endpoint - Yahoo Finance

May 24, 2025
pulisher
May 23, 2025

Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer - simplywall.st

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences (GILD) Achieves Key Trial Milestone with Trodelv - GuruFocus

May 23, 2025
pulisher
May 23, 2025

After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial - Fierce Pharma

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) Announces Promising Results from Trodelvy Study | - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Gilead posts trial win for Trodelvy in breast cancer (GILD) - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) Announces Promising Results from Trodelvy Study | GILD Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

ASCENT-03Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study - StreetInsider

May 23, 2025
pulisher
May 23, 2025

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - Business Wire

May 23, 2025
pulisher
May 23, 2025

Gilead records another pivotal study success for Trodelvy in first-line TNBC - FirstWord Pharma

May 23, 2025
pulisher
May 22, 2025

Sector Update: Health Care Stocks Softer Late Afternoon - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Sector Update: Health Care Stocks Retreat Thursday Afternoon - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gilead (GILD) Experiences Significant Increase in Bearish Options Activity | GILD Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gilead Sciences to Acquire HOOKIPA Pharma Assets for $10M - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha

May 22, 2025
pulisher
May 22, 2025

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs - Fierce Biotech

May 22, 2025
pulisher
May 22, 2025

Hookipa Pharma Sells Assets to Gilead Sciences - TipRanks

May 22, 2025
pulisher
May 21, 2025

What Analysts Are Saying About Gilead Sciences Stock - Benzinga

May 21, 2025
pulisher
May 21, 2025

Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research - CSRwire

May 21, 2025
pulisher
May 21, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Gilead Sciences (GILD) Receives Hold Rating from Needham | GILD Stock News - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now? - Zacks Investment Research

May 20, 2025
drug_manufacturers_general PFE
$23.49
price up icon 0.17%
$288.18
price up icon 1.64%
drug_manufacturers_general GSK
$41.03
price up icon 2.58%
drug_manufacturers_general MRK
$76.84
price up icon 0.58%
drug_manufacturers_general NVO
$71.50
price up icon 2.94%
자본화:     |  볼륨(24시간):